Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CytomX, Pfizer deal

CytomX partnered with Pfizer to develop and commercialize multiple Probody-drug conjugates (PDCs) in undisclosed cancer indications.

Read the full 168 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE